JP5945096B2 - 抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用 - Google Patents

抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用 Download PDF

Info

Publication number
JP5945096B2
JP5945096B2 JP2010542454A JP2010542454A JP5945096B2 JP 5945096 B2 JP5945096 B2 JP 5945096B2 JP 2010542454 A JP2010542454 A JP 2010542454A JP 2010542454 A JP2010542454 A JP 2010542454A JP 5945096 B2 JP5945096 B2 JP 5945096B2
Authority
JP
Japan
Prior art keywords
cancer
antibody
human
administration
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010542454A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011526674A5 (https=
JP2011526674A (ja
Inventor
史朗 柴山
史朗 柴山
隆雄 吉田
隆雄 吉田
多門 林
多門 林
林　昭夫
昭夫 林
村井　淳
淳 村井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Priority to JP2010542454A priority Critical patent/JP5945096B2/ja
Publication of JP2011526674A publication Critical patent/JP2011526674A/ja
Publication of JP2011526674A5 publication Critical patent/JP2011526674A5/ja
Application granted granted Critical
Publication of JP5945096B2 publication Critical patent/JP5945096B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
JP2010542454A 2008-07-04 2009-07-03 抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用 Expired - Fee Related JP5945096B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010542454A JP5945096B2 (ja) 2008-07-04 2009-07-03 抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2008176110 2008-07-04
JP2008176110 2008-07-04
JP2010542454A JP5945096B2 (ja) 2008-07-04 2009-07-03 抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用
PCT/JP2009/003093 WO2010001617A1 (en) 2008-07-04 2009-07-03 Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human pd-1 antibody on cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014223954A Division JP2015061844A (ja) 2008-07-04 2014-11-04 抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用

Publications (3)

Publication Number Publication Date
JP2011526674A JP2011526674A (ja) 2011-10-13
JP2011526674A5 JP2011526674A5 (https=) 2012-08-16
JP5945096B2 true JP5945096B2 (ja) 2016-07-05

Family

ID=41465723

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010542454A Expired - Fee Related JP5945096B2 (ja) 2008-07-04 2009-07-03 抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用
JP2014223954A Withdrawn JP2015061844A (ja) 2008-07-04 2014-11-04 抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014223954A Withdrawn JP2015061844A (ja) 2008-07-04 2014-11-04 抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用

Country Status (4)

Country Link
US (1) US8460886B2 (https=)
EP (1) EP2307050A4 (https=)
JP (2) JP5945096B2 (https=)
WO (1) WO2010001617A1 (https=)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481271A (zh) 2009-05-11 2012-05-30 博格生物系统有限责任公司 利用表观代谢转变剂、多维细胞内分子或环境影响剂治疗代谢障碍的方法
PT2435825E (pt) 2009-05-27 2015-11-02 Biotempus Ltd Métodos para o tratamento de doenças
ES2928585T3 (es) * 2010-09-21 2022-11-21 Proteomics Int Pty Ltd Biomarcadores asociados con prediabetes, diabetes y condiciones relacionadas con diabetes
PT2691112T (pt) * 2011-03-31 2018-07-10 Merck Sharp & Dohme Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
ES2616289T3 (es) * 2012-03-01 2017-06-12 Miltenyi Biotec Gmbh Separación de neuronas vivas intactas
WO2013169693A1 (en) * 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
US20150177250A1 (en) * 2012-06-18 2015-06-25 Mayo Foundation For Medical Education And Research Determination of efficient time(s) for chemotherapy delivery
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
NZ713868A (en) 2013-04-08 2021-12-24 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
SMT202100065T1 (it) 2013-05-02 2021-03-15 Anaptysbio Inc Anticorpi diretti contro la proteina della morte programmata (pd-1)
KR102370843B1 (ko) 2013-09-04 2022-03-04 버그 엘엘씨 코엔자임 q10의 연속주입에 의한 암치료 방법
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
SG10201804945WA (en) 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
HUE045065T2 (hu) 2014-01-31 2019-12-30 Novartis Ag TIM-3 antitest molekulák és felhasználásaik
KR20240144452A (ko) * 2014-03-05 2024-10-02 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
JP6991857B2 (ja) 2014-10-10 2022-01-13 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療
JP6821560B2 (ja) 2014-10-21 2021-01-27 サイクロン ファーマシューティカルズ インターナショナル エルティーディー．Ｓｃｉｃｌｏｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｔｄ． 免疫刺激剤による癌治療
EP3212670B1 (en) * 2014-10-29 2020-12-23 Five Prime Therapeutics, Inc. Combination therapy for cancer
JP2016148623A (ja) * 2015-02-13 2016-08-18 京都府公立大学法人 大腸がんの検出方法
AU2016249981B2 (en) 2015-04-13 2022-02-17 Five Prime Therapeutics, Inc. Combination therapy for cancer
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
HRP20211058T8 (hr) 2015-07-29 2021-11-26 Novartis Ag Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
HUE068868T2 (hu) 2015-07-30 2025-02-28 Macrogenics Inc PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
JP6666916B2 (ja) * 2015-08-06 2020-03-18 積水メディカル株式会社 腎疾患の検査方法
EP4458417A3 (en) 2015-08-11 2025-02-19 Wuxi Biologics Ireland Limited Novel anti-pd-1 antibodies
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
IL260021B (en) 2015-12-14 2022-09-01 Macrogenics Inc Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them
JP7137474B2 (ja) 2016-03-15 2022-09-14 メルサナ セラピューティクス，インコーポレイティド ＮａＰｉ２ｂ標的化抗体－薬物コンジュゲート及びその使用方法
US20180021270A1 (en) * 2016-07-21 2018-01-25 Berg Llc Methods for the treatment of cancer using coenzyme q10 in combination with immune checkpoint modulators
WO2018022438A1 (en) * 2016-07-29 2018-02-01 Eli Lilly And Company Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer
JP2019533458A (ja) 2016-11-01 2019-11-21 アナプティスバイオ インコーポレイティッド プログラム死１（ｐｄ−１）に対する抗体
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
AU2018206481B2 (en) 2017-01-09 2025-02-27 Tesaro, Inc. Methods of treating cancer with anti-PD-1 antibodies
US20180271996A1 (en) 2017-02-28 2018-09-27 Mersana Therapeutics, Inc. Combination therapies of her2-targeted antibody-drug conjugates
JP7257967B2 (ja) * 2017-05-01 2023-04-14 ザ チルドレンズ メディカル センター コーポレーション 抗ｐｄ１抗体試薬に関する方法および組成物
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
JP7382232B2 (ja) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
WO2018225063A1 (en) * 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor
US12016900B2 (en) 2017-06-04 2024-06-25 Rappaport Family Institute For Research In The Medical Sciences Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent
US12070489B2 (en) 2018-12-12 2024-08-27 Rappaport Family Institute For Research In The Medical Sciences Method of treating cancer with a cancer therapy in combination with another therapeutic agent
EP3681535A1 (en) 2017-09-13 2020-07-22 Five Prime Therapeutics, Inc. Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
US11946937B2 (en) * 2017-09-13 2024-04-02 Mayo Foundation For Medical Education And Research Identification and monitoring of apoptosis inhibitor of macrophage
WO2019104289A1 (en) 2017-11-27 2019-05-31 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
CN111757757A (zh) 2017-12-21 2020-10-09 梅尔莎纳医疗公司 吡咯并苯并二氮呯抗体共轭物
US12448448B2 (en) 2018-06-20 2025-10-21 Incyte Corporation Anti-PD-1 antibodies and uses thereof
WO2020081408A1 (en) 2018-10-18 2020-04-23 Merck Sharp & Dohme Corp. Formulations of anti-rsv antibodies and methods of use thereof
CN113365664A (zh) 2018-10-29 2021-09-07 梅尔莎纳医疗公司 具有含肽接头的半胱氨酸工程化的抗体-药物缀合物
MX2021004928A (es) 2018-10-31 2021-06-08 Merck Sharp & Dohme Llc Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos.
EP3876990A4 (en) 2018-11-07 2023-09-06 Merck Sharp & Dohme LLC CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
EP3924521A4 (en) 2019-02-15 2023-03-29 IncellDx, Inc. BLADDER-ASSOCIATED SAMPLES TESTING, IDENTIFICATION AND TREATMENT OF BLADDER-ASSOCIATED NEOPLASIA, AND KITS FOR USE THEREON
WO2020227431A1 (en) 2019-05-06 2020-11-12 Brown University Bispecific antibodies against chi3l1 and pd1 with enhanced t cell-mediated cytotoxic effects on tumor cells
WO2021061749A1 (en) 2019-09-24 2021-04-01 Mirati Therapeutics, Inc. Combination therapies
WO2023017525A1 (en) 2021-08-11 2023-02-16 OncoHost Ltd. Predicting patient response
WO2023236099A1 (en) * 2022-06-08 2023-12-14 Zhejiang Shimai Pharmaceutical Co., Ltd. Antibodies against enpp3 and uses thereof
EP4650781A1 (en) * 2023-01-10 2025-11-19 Toru Miyazaki Method for diagnosing cancer
WO2025034883A1 (en) 2023-08-08 2025-02-13 Quanta Therapeutics, Inc. Combination therapies with kras modulators
WO2025106905A1 (en) 2023-11-17 2025-05-22 Quanta Therapeutics, Inc. Combination therapies with a kras modulator and an immunomodulator inhibitor
WO2026060384A1 (en) 2024-09-16 2026-03-19 Quanta Therapeutics, Inc. Combination therapies with kras modulators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07291996A (ja) 1994-03-01 1995-11-07 Yuu Honshiyo ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物
AU2003281200A1 (en) * 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
DK2439273T3 (da) * 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
US20100004871A1 (en) * 2005-12-27 2010-01-07 Power3 Medical Products, Inc. Identities, specificities, and use of twenty two (22) differentially expressed protein biomarkers for blood based diagnosis of breast cancer

Also Published As

Publication number Publication date
JP2011526674A (ja) 2011-10-13
JP2015061844A (ja) 2015-04-02
EP2307050A1 (en) 2011-04-13
WO2010001617A1 (en) 2010-01-07
US8460886B2 (en) 2013-06-11
EP2307050A4 (en) 2012-07-25
US20110123550A1 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
JP5945096B2 (ja) 抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用
US10968273B2 (en) Antibody recognizing human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
JP5792121B2 (ja) 癌、特に乳癌、甲状腺癌及び肺癌のインビトロ診断のためのＰｒｏＮＧＦアッセイのための方法とＰｒｏＮＧＦの治療的使用
BR112012032008B1 (pt) Anticorpos s100a4, linhagem celular de hibridoma, composição farmacêutica, conjugado, método e kit para diagnosticar câncer ou uma doença associada à inflamação
CN101553728B (zh) 颗粒体蛋白-上皮素前体(gep)抗体用于检测和抑制肝细胞癌(hcc)的用途
EP2984108A1 (en) Anti-s100a7 antibodies for the treatment and diagnosis of cancer
US9850303B2 (en) Hybridoma clones and monoclonal antibodies to tetraspanin 8
Kim et al. Targeting metastatic breast cancer with peptide epitopes derived from autocatalytic loop of Prss14/ST14 membrane serine protease and with monoclonal antibodies
US9862773B2 (en) Hybridoma clones and monoclonal antibodies to CD9
US20080199470A1 (en) The Use of Granulin-Epithelin Precursor (GEP) Anitbodies for Detection and Suppression of Hepatocellular Carcinoma (HCC)
US9206258B2 (en) Anti-prostate cancer antibodies and methods of detection and treatment of prostate cancer using the same
Taher et al. Immunohistochemical Expression of CD34 as Biological Marker of Angiogenesis and Expression of D2-40 as Marker of Lymphangiogenesis in Mucoepidermoid Carcinoma of Salivary Glands.
CN105474016B (zh) Augurin免疫试验
EP4729544A1 (en) Use of claudin-3 as target for diagnosis and treatment of small cell lung cancer
WO2024194495A1 (en) C3f assay
HK1220763B (zh) Augurin免疫试验
JP2014185101A (ja) 細胞の転移又は浸潤抑制剤
HK40003673A (en) Monoclonal antibody and application thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120628

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130813

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131031

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131210

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140110

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20140411

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141104

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20141201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150202

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150224

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20150410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160328

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160527

R150 Certificate of patent or registration of utility model

Ref document number: 5945096

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees